| Halaven (eribulin mesylate) / Eisai |
| Completed | 2a | 53 | Europe | Eribulina | MedSIR | Breast Neoplasm, Metastasis | 12/15 | 12/15 | | |
2ND-STEP, jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib |
|
|
| Active, not recruiting | 2 | 120 | Japan | Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene | Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development | Advanced soft tissue sarcoma | | | | |
NCT00097721: A Study of E7389 in Advanced/Metastatic Breast Cancer Patients |
|
|
| Completed | 2 | 104 | US | E7389 | Eisai Inc. | Breast Neoplasms | 11/06 | 11/06 | | |
NCT00246090 / 2005-003656-35: A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine |
|
|
| Completed | 2 | 298 | US, Canada | E7389 | Eisai Inc., Eisai Limited | Breast Cancer | 09/07 | 09/07 | | |
NCT00278993 / 2005-004271-37: Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy |
|
|
| Completed | 2 | 108 | US | E7389 | Eisai Inc. | Prostate Cancer | 01/08 | 01/08 | | |
NCT00100932: Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy |
|
|
| Completed | 2 | 106 | US | E7389 28 Day Cycle, E7389 21 Day Cycle | Eisai Inc. | Non-Small-Cell Lung Carcinoma | 06/08 | | | |
NCT00337129: S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
|
|
| Completed | 2 | 42 | US | eribulin mesylate, E7389 | National Cancer Institute (NCI) | Head and Neck Cancer | 08/08 | 07/11 | | |
NCT00337077: Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy |
|
|
| Completed | 2 | 121 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer | 06/09 | 11/13 | | |
NCT00633100: Phase II Clinical Study of E7389 for Advanced or Relapsed Breast Cancer |
|
|
| Completed | 2 | 81 | Japan | E7389 | Eisai Co., Ltd. | Breast Cancer | 09/09 | 09/09 | | |
NCT00965523: Study of E7389 for Advanced or Metastatic Breast Cancer |
|
|
| Completed | 2 | 81 | Japan | Eribulin Mesylate | Eisai Co., Ltd. | Breast Cancer | 12/10 | 01/11 | | |
NCT00400829: E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 66 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | 01/11 | 01/11 | | |
NCT01104155: Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 123 | US, RoW | eribulin mesylate + erlotinib | Eisai Inc. | Non-small Cell Lung Cancer | 04/11 | 01/17 | | |
|
NCT00383760: Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients |
|
|
| Completed | 2 | 15 | Canada | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer | 07/11 | 07/11 | | |
NCT00334893: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
|
|
| Completed | 2 | 74 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer | 03/12 | 03/12 | | |
NCT01268150: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer |
|
|
| Completed | 2 | 56 | US | Eribulin mesylate | Eisai Inc. | Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative) | 03/12 | 08/13 | | |
NCT00413192 / 2005-004272-20: E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma |
|
|
| Completed | 2 | 128 | Europe | E7389 | Eisai Inc. | Soft Tissue Sarcoma | 06/12 | 02/13 | | |
EMERGE, NCT01156753: A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer |
|
|
| Completed | 2 | 120 | US | CDX-011, "Investigator's Choice" chemotherapy | Celldex Therapeutics | Breast Cancer | 10/12 | 11/12 | | |
|
|
|
|
NCT01439282: Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer |
|
|
| Completed | 2 | 77 | US | eribulin mesylate, BOLD, Halaven, E7389, capecitabine, Xeloda | Eisai Inc. | Estrogen Receptor Positive Tumor, Breast Cancer | 11/12 | 05/14 | | |
|
NCT01269346: Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer |
|
|
| Completed | 2 | 52 | US | Eribulin Mesylate | Eisai Inc. | Breast Cancer | 03/13 | 05/16 | | |
|
NCT00879086: A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer |
|
|
| Completed | 2 | 104 | US | Eribulin Mesylate, E7389, Ixabepilone | Eisai Inc. | Breast Cancer | 04/13 | 04/14 | | |
|
NCT01427933: A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer |
|
|
| Completed | 2 | 141 | US | Ramucirumab (IMC-1121B), LY3009806, Eribulin | Eli Lilly and Company | Breast Cancer | 09/13 | 06/14 | | |
|
|
NCT01705691: Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer |
|
|
| Completed | 2 | 50 | Canada, US | Paclitaxel, Eribulin, eribulin mesylate, Doxorubicin, Cyclophosphamide | NSABP Foundation Inc, Eisai Inc. | Breast Cancer, HER2-negative Breast Cancer | 03/14 | 10/15 | | |
| Terminated | 2 | 7 | US, Europe | AEZS-108, Zoptarelin doxorubicin, SCCC, Standard single agent cytotoxic chemotherapy, Dexamethasone | AEterna Zentaris | Breast Cancer | 08/14 | 10/14 | | |
| Completed | 2 | 61 | Europe | Eribulin, Drug: Bevacizumab | ARCAGY/ GINECO GROUP | Metastatic Breast Cancer | 08/14 | 03/16 | | |
NCT01527487: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer |
|
|
| Completed | 2 | 76 | US | Eribulin, Halaven, Cyclophosphamide, Cytoxan, Docetaxel, Taxotere | SCRI Development Innovations, LLC, Eisai Inc. | HER2 Negative Breast Cancer | 09/14 | 07/16 | | |
NCT01328249: Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer |
|
|
| Completed | 2 | 81 | US | eribulin mesylate | Eisai Inc. | HER2-normal | 10/14 | 10/17 | | |
NCT01458249: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) |
|
|
| Completed | 2 | 52 | Japan | eribulin mesylate, E7389 | Eisai Co., Ltd. | Soft Tissue Sarcoma | 11/14 | 02/16 | | |
| Terminated | 2 | 43 | Europe | Lapatinib + 1,23 mg Eribulin, Lapatinib + 1,76 mg Eribulin | German Breast Group | Metastatic Breast Cancer | 03/15 | 03/15 | | |
NCT01498588: Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer |
|
|
| Terminated | 2 | 7 | US | Eribulin, Halaven, Doxorubicin, Adriamycin, Cyclophosphamide, Cytoxan, Pegfilgrastim, Neulasta | Emory University, Eisai Inc. | Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of the Breast, Neoplasms, Breast, Tumors, Breast | 06/15 | 06/15 | | |
| Completed | 2 | 163 | Europe | Eribulin, Halaven(R) | SOLTI Breast Cancer Research Group, Eisai Inc. | Breast Cancer | 06/15 | 06/15 | | |
| Completed | 2 | 19 | Canada, US | Eribulin Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Pharmacological Study | National Cancer Institute (NCI) | Recurrent Osteosarcoma | 06/15 | 03/20 | | |
NCT02000596: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. |
|
|
| Terminated | 2 | 2 | US | Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Anastrozole (Arimidex), Fulvestrant (Faslodex), Chemotherapy with Eribulin | University of Maryland, Baltimore, Genentech, Inc. | Metastatic Breast Cancer | 11/15 | 01/16 | | |
2012-003505-10: Gemcitabine and Eribulin as first line treatment of advanced triple-negative breast cancer. Gemcitabina ed Eribulina come trattamento di prima linea nel carcinoma mammario triplo-negativo in fase avanzata. |
|
|
| Ongoing | 2 | 83 | Europe | GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML, GEMCITABINA HOS.IT*INF FL 1G, HALAVEN*EV 6FL 2ML 0,44MG/ML | GRUPPO ONCOLOGICO ITALIANO DI RICERCA, EISAI Srl | Locally recurrent or metastatic triple negative breast cancer. Pazienti con tumore della mammella triplo negativo con recidiva locale o metastatico. | | | | |
| Completed | 2 | 83 | US | Eribulin, E7389, Halaven, ER-086526, NSC-707389 | Dana-Farber Cancer Institute | Breast Cancer | 05/16 | 05/16 | | |
NCT01912963: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer |
|
|
| Terminated | 2 | 32 | US | Pertuzumab, Perjeta, Trastuzumab, Herceptin, eribulin, eribulin mesylate, Halaven | Dana-Farber Cancer Institute, Eisai Inc., Genentech, Inc. | HER2-positive Breast Cancer, Metastatic Breast Cancer | 12/16 | 12/16 | | |
| Unknown status | 2 | 61 | Europe | Bevacizumab and eribulin, Halaven, Avastin | Consorzio Oncotech, Clinical Research Technology S.r.l. | Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 12/16 | 12/17 | | |
NCT02481050: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer |
|
|
| Completed | 2 | 58 | US | Eribulin Mesylate, Halaven, E7389 | Eisai Inc. | Breast Cancer | 12/16 | 09/17 | | |
NCT01401959: Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy |
|
|
| Completed | 2 | 127 | US | Eribulin, Halaven, Trastuzumab, Herceptin | SCRI Development Innovations, LLC, Eisai Inc. | Metastatic Breast Cancer | 04/17 | 04/17 | | |
NCT02263495: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer |
|
|
| Completed | 2 | 118 | RoW | Paclitaxel, Genexol,, Eribulin, Halaven,, Gemcitabine, Gemcit | Asan Medical Center, Eisai Inc., Dong-A ST Co., Ltd., Samyang Biopharmaceuticals Corporation | Metastatic Breast Cancer | 05/17 | 06/19 | | |
NCT02215876: Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | Doxorubicin, Cyclophosphamide, Eribulin | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Breast Cancer | 08/17 | 03/20 | | |
NCT01613768: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer |
|
|
| Completed | 2 | 29 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | University of Washington, National Cancer Institute (NCI) | Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer | 08/17 | 08/17 | | |
2017-003621-15: A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribulina in combinazione con capecitabina per il trattamento di seconda linea in pazienti affetti da carcinoma pancreatico avanzato dopo fallimento di terapia di prima linea con gemcitabina/abraxane. |
|
|
| Not yet recruiting | 2 | 25 | Europe | HALAVEN, Capecitabina accord 150, Capecitabina Accord 500, [-], Solution for infusion, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, CAPECITABINA ACCORD - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE | AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA, EISAI srl | advanced pancreatic cancer tumore del pancreas avanzato, advanced pancreatic cancer tumore del pancreas avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-004652-35: Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea seguita da CApecitabina o sequenza inversa in pazienti con carcinoma mammario metastatico (MBC) HER2-negativo: uno studio randomizzato di fase II – Studio ERICA |
|
|
| Ongoing | 2 | 150 | Europe | HALAVEN, Xeloda, [Eribulina], [Capecitabina], Solution for injection, Film-coated tablet, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI, XELODA - 500 MG 120 COMPRESSE FILMRIVESTITE IN BLISTER USO ORALE | CONSORZIO ONCOTECH, EISAI S.r.l. | HER2-negative Metastatic Breast Cancer Carcinoma mammario metastatico HER2-negativo, Metastatic Breast Tumour Tumore al seno metastatico, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 64 | Europe | Vargatef, EMEA/H/C/002569, Tablet, Powder for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Powder for injection, Solution for infusion, , Capsule, Suspension for injection, Powder for concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion, Capsule, soft, Concentrate for solution for injection, Concentrate and solvent for solution for injection/infusion, Powder for solution for infusion, Implant, Kit for radiopharmaceutical preparation, Capsule, hard, Solution for injection/infusion, Powder and solvent for solution for injection, Solution for injection in pre-filled syringe, Concentrate and solvent for solution for infusion, Powder for solution for injection, Powder and solvent for solution for injection in pre-filled syringe, Concentrate and solvent for concentrate for solution for infusion, Solution for injection, Zytiga, Kadcyla, Giotrif, Arimidex, Trisenox, Erwinase, Inlyta, Vidaza, Levact, Avastin, Bleomycin, Velcade, Bosulif, Adcetris, Jevtana, Xeloda, Carboplatin, Erbitux, Leukeran, Cisplatin, Evoltra, Xalkori, Endoxan powder and capsule, Alexan and Cytarabin, Tafinlar, DepoCyte, Dacarbazin Lipomed, Sprycel, Daunoblastin, Dacogen, Firmagon, Docetaxel and Taxotere, Myocet, Caelyx, Epirubicin and Farmorubicin, Xtandi, Halaven, Tarceva, Etoposid concentrate and Vepesid capsule, Afinitor, Exemestan and Aromasin, Faslodex, Neoflubin, 5-Fluorouracil "Ebewe", Iressa, Gemzar, Zoladex, Zevalin, Imbruvica, Holoxan, Glivec, IntronA, Yervoy, Irinotecan, Tyverb, Revlimid, Femara, Calciumfolinat, Eligard Depot and Trenantone, Puri-Nethol and Xaluprine suspension, Methotrexat "Lederle" and Ebetrexat, Methotrexat and Ebetrexat, Metoject PEN and Ebetrexat and Methotrexat, Mitomycin C, Tasigna, Gazyvaro, Arzerra, Eloxatin and Ebeoxal and Oxaliplatin, Abraxane and Ebetaxel and Paclitaxel, Vectibix, Votrient, PegIntron and ViraferonPeg, PegIntron and ViraferonPeg injector, Alimta, Perjeta, Imnovid, Iclusig, Fortecortin and Aprednislon, Stivarga, MabThera, Jakavi, Nexavar, Sutent, Nolvadex, Temozolomide SUN, Torisel, Thalidomide, Hycamitin, Fareston, Mekinist, Herceptin and Kadcyla, Zelboraf, Velbe, Oncovin and Vincristin, Navelbine and Eberelbin, Zaltrap, Vargatef | Medical University of Graz, Medical University of Graz | Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected., Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established., Diseases [C] - Cancer [C04] | | | | |
NCT02581839: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate |
|
|
| Completed | 2 | 9 | US | Eribulin Mesylate, Halaven, MRI, Magnetic Resonance Imaging, Pre-Medication: Zofran, Pre-Medication: Decadron | Case Comprehensive Cancer Center | Metastatic Breast Cancer, Brain Metastases | 07/18 | 07/20 | | |
| Terminated | 2 | 8 | Europe | Eribulin, Halaven | Imperial College London | Breast Cancer | 07/18 | 07/18 | | |
NCT03051659: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer |
|
|
| Completed | 2 | 90 | US | Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda | Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC | Breast Cancer | 10/18 | 09/23 | | |
|
| Completed | 2 | 44 | Europe | Pembrolizumab, Keytruda, MK3475, Eribulin, Halaven | MedSIR | Breast Cancer | 10/18 | 12/20 | | |
NCT02178241: Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 26 | Canada, US | Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011 | National Cancer Institute (NCI) | Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma | 03/19 | 07/19 | | |
NCT03032614: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients |
|
|
| Withdrawn | 2 | 0 | NA | Carboplatin, Paraplatin, Eribulin, Halaven, E7389, Veliparib, ABT-888 | The University of Texas Health Science Center at San Antonio | Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation | 03/19 | 04/20 | | |
2018-004571-12: Trial in advanced Solitary Fibrous Tumor (SFT) Studio clinico nel Tumore Fibroso Solitario (TFS) |
|
|
| Not yet recruiting | 2 | 20 | Europe | Eribulina, [30058], Solution for injection, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI | ITALIAN SARCOMA GROUP, Eisai Italy | Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Diseases [C] - Cancer [C04] | | | | |
NCT01908101: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer |
|
|
| Completed | 2 | 86 | US | Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Laboratory Biomarker Analysis | University of Washington, National Cancer Institute (NCI) | Recurrent Breast Carcinoma, Stage IV Breast Cancer | 05/19 | 05/19 | | |
NCT02788201: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
|
|
| Completed | 2 | 8 | US | 75 approved agents, COXEN | National Cancer Institute (NCI) | Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms | 10/19 | 10/19 | | |
| Withdrawn | 2 | 0 | Europe | Eribulin | Institut Paoli-Calmettes, Eisai Inc. | Metastatic Breast Cancer | 04/20 | 04/20 | | |
NCT03412955: A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes |
|
|
| Unknown status | 2 | 14 | RoW | Eribulin Mesylate | Tan Tock Seng Hospital | Breast Cancer | 04/20 | 04/20 | | |
NCT01372579: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients |
|
|
| Unknown status | 2 | 30 | US | eribulin mesylate, Halaven, B1939, E7389, ER-086526, halichrondrin B analog, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, biopsy, biopsies | Northwestern University, Eisai Inc. | Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer | 06/20 | 06/21 | | |
NCT01593020: Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 |
|
|
| Completed | 2 | 54 | US | Paclitaxel, Taxol, Eribulin, E7389, 5-Fluorouracil, 5-FU, Adrucil, Efudex, Epirubicin, Ellence, Cyclophosphamide, Cytoxan, Neosar, Doxorubicin, Doxorubicin Hydrochloride, Adriamycin PFS, Adriamycin RDF, Adriamycin, Rubex | M.D. Anderson Cancer Center, Eisai Inc. | Breast Cancer | 11/20 | 11/20 | | |
NCT02640508: Eribulin and Lenvatinib in Advanced Solid Tumors |
|
|
| Completed | 2 | 29 | US | Eribulin, Halaven, Lenvatinib, Lenvima | Virginia G. Kaklamani, Eisai Inc. | Cancer, Solid Tumor | 11/20 | 01/23 | | |
| Terminated | 2 | 78 | Europe | Eribulin mesilate, Halaven | Swiss Group for Clinical Cancer Research | Breast Cancer, Adenocarcinoma | 12/20 | 07/21 | | |
NCT03441360 / 2018-001282-17: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) |
|
|
| Completed | 2 | 23 | US | Eribulin mesylate | Eisai Inc. | Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma | 01/21 | 01/22 | | |
2020-004909-32: Can treatment with Eribulin chemotherapy restore the sentivity in cancertissue in subsequent treatment with antihormon treatment? A study for patients with ER positive, HER2 normal breast cancer. Kan behandling med kemoterapien eribulin genskabe kræftvævets følsomhed for efterfølgende antihormonbehandling. Et studie til patienter med ER positiv, HER2 normal brystkræft. |
|
|
| Not yet recruiting | 2 | 42 | Europe | Halaven, Concentrate and solvent for solution for infusion, Tablet, Halaven, Aromasin | Department of Oncology, Department of oncology, University Hospital of Aarhus, Skejby | Metastatic breast cancer with estrogene positive and HER2 normal/negative subtype. Metastatisk brystkræft med østrogenreceptor positive og HER2 normal/negative HER2 receptor status., Breast cancer with has spred to other organs with is sentitive to estrogen and has a normal HER2 receptor status. Brystkræft med spredning til andre organer som er østrogen receptor positive og har HER2 normal udtryk ved immunhistokemi., Diseases [C] - Cancer [C04] | | | | |
NCT01676818: Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer |
|
|
| Completed | 2 | 32 | US | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | University of Southern California, National Cancer Institute (NCI) | Recurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer | 02/21 | 08/21 | | |
2017-004324-30: Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patients Ensayo clínico para estudiar el efecto de tratamiento con eribulina y terapia endocrina en pacientes con cáncer de mama avanzado |
|
|
| Not yet recruiting | 2 | 60 | Europe | Solution for injection, HALAVEN | Medica Scientia Innovation Research (MEDSIR), EISAI FARMACEUTICA S.A. | Luminal Metastatic Breast Cancer Cáncer de mama metastásico luminal, Metastatic Breast Cancer Cáncer de mama metastásico, Diseases [C] - Cancer [C04] | | | | |
REVERT, NCT03795012: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients |
|
|
| Terminated | 2 | 22 | Europe | Eribulin, Halaven | MedSIR | Breast Cancer | 03/21 | 03/21 | | |
NCT02623972: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer |
|
|
| Active, not recruiting | 2 | 22 | US | Eribulin, Halaven, B1939 mesylate, Adriamycin, Doxorubicin, Cyclophosphamide, Cytoxan®, Neosar® | Dana-Farber Cancer Institute, Eisai Inc. | Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | 05/21 | 12/26 | | |
ACTRN12618000357257: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 5 substudy 10: Eribulin |
|
|
| Completed | 2 | 16 | | | The University of Sydney, Office for Health and Medical Research | Cancer
, Sarcoma, Angiosarcoma | | | | |
NCT05206656: Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer |
|
|
| Completed | 2 | 80 | RoW | Eribulin Mesylate, Anlotinib | Hunan Cancer Hospital | Metastatic Breast Cancer | 04/22 | 07/22 | | |
NCT03810976: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma |
|
|
| Completed | 2 | 37 | RoW | Eribulin, gemcitabine | Yonsei University | Sarcoma | 05/22 | 05/22 | | |
NCT04624711: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Eribulin Mesylate, Halaven, Anlotinib hydrochloride, Anlotinib | The First Affiliated Hospital with Nanjing Medical University | HER2-negative Breast Cancer | 06/22 | 12/22 | | |
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study |
|
|
| Not yet recruiting | 2 | 265 | RoW | Eribulin, Tislelizumab | Fudan University | Triple Negative Breast Cancer | 06/22 | 06/23 | | |
NCT03331250: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) |
|
|
| Active, not recruiting | 2 | 13 | US | Eribulin, Halaven | Massachusetts General Hospital, Eisai Inc. | Angiosarcoma, Epithelioid Hemangioendothelioma | 07/23 | 05/25 | | |
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2 | 160 | RoW | Eribulin,cisplatin, Gemcitabine,cisplatin | Fudan University | Breast Cancer | 07/22 | 10/22 | | |
| Active, not recruiting | 2 | 46 | RoW | Camrelizumab, Apatinib, Eribulin, Eribulin Mesylate | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 11/22 | 08/23 | | |
| Active, not recruiting | 2 | 1460 | Europe | AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736 | UNICANCER, Fondation ARC, AstraZeneca | Metastatic Breast Cancer | 12/22 | 12/24 | | |
NCT05546255: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 40 | RoW | Eribulin Mesylate, Lobaplatin | Chinese Academy of Medical Sciences | Triple Negative Breast Cancer | 12/22 | 12/23 | | |
NCT05402722: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Eribulin, Halaven, anti-PD-1 antibody | Beijing 302 Hospital | TNBC - Triple-Negative Breast Cancer | 12/22 | 06/23 | | |
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Fudan University | Triple Negative Breast Cancer | 01/23 | 01/23 | | |
2022-001398-30: PHASE II STUDY WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN FOR ADVANCED METAPLASTIC BREAST CANCER. ESTUDIO FASE II CON MEN1611 EN MONOTERAPIA O EN COMBINACION CON ERIBULINA EN PACIENTES CON CANCER DE MAMA METAPLÁSICO AVANZADO |
|
|
| Not yet recruiting | 2 | 28 | Europe | MEN1611, Halaven, MEN1611, Halaven, Capsule, Injection/infusion, Halaven | Medica Scientia Innovation Research, S.L., Menarini SRL | Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolog (PTEN)-altered, unresectable locally advanced or metastatic metaplastic breast carcinoma (MpBC) , Advanced or metastatic metaplastic breast cancer Cancer de mama metaplasico avanzado, Diseases [C] - Cancer [C04] | | | | |
EMBRAVE-001, NCT04502680: Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients |
|
|
| Not yet recruiting | 2 | 100 | RoW | Eribulin Mesylate, Halaven | The First Affiliated Hospital with Nanjing Medical University | Triple Negative Breast Cancer | 06/23 | 06/24 | | |
| Active, not recruiting | 2 | 122 | Europe | Eribulin Mesylate, Eribulin, Capecitabine | Consorzio Oncotech, EISAI S.r.l. | Metastatic Breast Cancer | 07/23 | 07/23 | | |
NCT03899805: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas |
|
|
| Active, not recruiting | 2 | 57 | US | Eribulin, Halaven, Pembrolizumab, Keytruda | Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC | Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma | 08/25 | 08/25 | | |
NCT04681911: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 71 | RoW | Inetetamab, Pyrotinib, Capecitabine, xeloda or other names, Gemcitabine, Gemzar or other names, Vinorelbine, Navelbine or other names, Carboplatin, Paraplatin or other names, Albumin paclitaxel, Abraxane or other names, Eribulin, Halaven | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 09/23 | 09/24 | | |
| Recruiting | 2 | 30 | US | Tucatinib, TUKYSA, Eribulin, HALAVEN, Trastuzumab, HERCEPTIN | Criterium, Inc. | Breast Cancer | 06/27 | 08/27 | | |
PATHFINDER, NCT04464174: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Completed | 2 | 54 | Europe | Ipatasertib, GDC-0068, Capecitabine, Xeloda, Eribulin, Halaven, Carboplatin, Paraplatin, Gemcitabine, Gemzar | MedSIR, Hoffmann-La Roche | Triple Negative Breast Cancer | 11/23 | 11/23 | | |
| Completed | 2 | 73 | Europe | Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1) | SOLTI Breast Cancer Research Group | Metastatic Breast Cancer | 09/23 | 11/23 | | |
ZDWY.XBZL.002, NCT05263882: Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 58 | NA | Gemcitabine combined with eribulin | Fifth Affiliated Hospital, Sun Yat-Sen University | HER2-negative Breast Cancer | 12/23 | 09/24 | | |
NCT03237780: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer |
|
|
| Active, not recruiting | 2 | 72 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526 Mesylate, Halaven, Halichondrin B Analog | National Cancer Institute (NCI) | Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma | 06/25 | 06/25 | | |
AK104-IIT-007, NCT06202313: Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 128 | RoW | Cadonilimab, AK104, Eribulin | Shengjing Hospital | Triple Negative Breast Cancer | 12/25 | 12/28 | | |
NCT05945368: A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC |
|
|
| Recruiting | 2 | 78 | RoW | Eribulin mesylate injection、Pertuzumab、Trastuzumab, Eribulin+HP | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HER2-positive Breast Cancer | 02/24 | 02/25 | | |
ESPERO, NCT05530057: Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer |
|
|
| Recruiting | 2 | 180 | RoW | Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar), Eribulin Mesylate | Seoul National University Hospital | Advanced Breast Cancer | 02/24 | 12/25 | | |
NCT06308939: Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial |
|
|
| Not yet recruiting | 2 | 81 | RoW | Eribulin, eribulin mesylate, Sintilimab | Zhejiang Cancer Hospital | Metastatic Breast Cancer | 12/25 | 08/26 | | |
ChiCTR2200059629: Eribulin plus anlotinib for the treatment of refractory and advanced soft tissue sarcoma after failure of standard therapy：a prospective, open-label, single arm and single center clinical study |
|
|
| Recruiting | 2 | 30 | | Eribulin plus anlotinib | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly self-funded，partly provied by Eisai China Inc. | Soft tissue Sarcoma | | | | |
| Completed | 2 | 16 | Europe | Eribulin, Intervention under investigation | Italian Sarcoma Group, Eisai Inc. | Solitary Fibrous Tumor | 09/24 | 09/24 | | |
NCT06355024: Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 10 | NA | Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum | Fudan University | Triple-negative Breast Cancer | 12/24 | 01/25 | | |
NCT06355037: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum | Fudan University | Triple-negative Breast Cancer | 12/24 | 01/25 | | |
| Recruiting | 2 | 120 | US | Paxman Scalp Cooling System, Scalp Cooling Cap, Eribulin, Halaven, Sacituzumab govitecan, Trodelvy, IMMU-132, Trastuzumab deruxtecan, Enhertu, DS-8201a | Dana-Farber Cancer Institute, Paxman Coolers Limited, AstraZeneca, Eisai Inc., Daiichi Sankyo, Gilead Sciences | Metastatic Breast Cancer, Chemotherapy-induced Alopecia | 06/26 | 06/28 | | |
NCT06387628: LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer |
|
|
| Recruiting | 2 | 74 | RoW | LM-108, Toripalimab, Eribulin, Nab paclitaxel | Fudan University | TNBC - Triple-Negative Breast Cancer | 04/26 | 04/27 | | |
NCT06539559: Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 60 | RoW | Eribulin, Halaven, Bevacizumab, Avastin | Wang Jiayu, Chinese Academy of Medical Sciences | Breast Neoplasms, Neoplasm Metastasis, Drug Therapy, Bevacizumab | 02/26 | 08/26 | | |
NCT06533722: Adaptive Therapy for Post-Second-Line Advanced Breast Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Gemcitabine, Vinorelbine, or Eribulin, chemotherapy | Sun Yat-sen University | HER2-negative Metastatic Breast Cancer | 01/25 | 07/25 | | |
NCT06678230: Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | Anlotinib, Eribulin | The First Hospital of Jilin University | Breast Cancer | 10/25 | 10/25 | | |
